Abnormal cellular apoptosis plays a pivotal role in the pathogenesis of Multiple Myeloma
(MM). Over the years, BCL-2, a crucial anti-apoptotic protein, has garnered significant …

Therapeutic developments targeting acute myeloid leukemia (AML) have been in the
pipeline for five decades and have recently resulted in the approval of multiple targeted …

Simple Summary Ovarian cancer is frequently discovered in the later stages. Current
treatment for advanced disease ovarian cancer is inadequate and survival is poor. Our goal …

SF3B1 mutations frequently occur in cancer yet lack targeted therapies. Clinical trials of
XPO1 inhibitors, selinexor and eltanexor, in high-risk myelodysplastic neoplasms (MDS) …

Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that
inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple …

Introduction Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in
the challenging landscape of relapsed/refractory multiple myeloma (RRMM). Areas covered …

Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple
myeloma (MM) have been made. Nevertheless, patients with MM resistant to …

Purpose Selinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted
accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM) …

The BCL2 inhibitor venetoclax has emerged as an effective treatment option for multiple
myeloma (MM), the second most common blood cancer. Despite the recent inclusion in …

Methods: In this study, we conducted a retrospective analysis to investigate the efficacy of
venetoclax-based therapy in relapsed/refractory myeloma patients with t (6; 14) …